Motus GI (NASDAQ:MOTS – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
20.1% of Motus GI shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 0.3% of Motus GI shares are owned by company insiders. Comparatively, 34.1% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Motus GI and InspireMD”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Motus GI | $319,000.00 | 0.00 | -$12.87 million | ($14.69) | 0.00 |
| InspireMD | $7.78 million | 8.99 | -$19.92 million | ($0.84) | -1.96 |
Motus GI has higher earnings, but lower revenue than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Motus GI has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
Profitability
This table compares Motus GI and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Motus GI | N/A | N/A | N/A |
| InspireMD | -413.96% | -69.42% | -57.68% |
Analyst Ratings
This is a summary of current ratings for Motus GI and InspireMD, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Motus GI | 0 | 0 | 0 | 0 | 0.00 |
| InspireMD | 0 | 0 | 1 | 0 | 3.00 |
InspireMD has a consensus target price of $4.00, suggesting a potential upside of 142.42%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Motus GI.
Summary
InspireMD beats Motus GI on 8 of the 14 factors compared between the two stocks.
About Motus GI
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.
